Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001343845 | SCV001537862 | likely benign | CHARGE syndrome | 2024-10-28 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002547427 | SCV003692439 | uncertain significance | Inborn genetic diseases | 2022-11-16 | criteria provided, single submitter | clinical testing | The c.778C>T (p.P260S) alteration is located in exon 2 (coding exon 1) of the CHD7 gene. This alteration results from a C to T substitution at nucleotide position 778, causing the proline (P) at amino acid position 260 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |